US Congress Subject | Drug safety, medical device, and laboratory regulation

Filter View [Reset All]
Syndicate content
StanceStateBillStatusSummary/TitleLast Actionsort icon
USSB4348Intro
25%
A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
[Detail][Text][Discuss]
2022-06-14
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
USHB7667Engross
50%
Reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices. ...
[Detail][Text][Discuss]
2022-06-09
Received in the Senate.
USHB623Intro
25%
Modifies funding for a pediatric disease research initiative within the National Institutes of Health (NIH). Currently, this initiative receives funding through FY2023 from the 10-Year Pediatric Research Initiative Fund. directs certain penalties ass...
[Detail][Text][Discuss]
2022-05-18
Ordered to be Reported (Amended) by the Yeas and Nays: 53 - 0.
USHB7669Intro
25%
To require guidance on extending expiration dates for certain drugs, and for other purposes.
[Detail][Text][Discuss]
2022-05-06
To House Energy And Commerce Committee
USHB7585Intro
25%
To improve the health of minority individuals, and for other purposes.
[Detail][Text][Discuss]
2022-04-27
To House Subcommittee on Economic Development, Public Buildings, and Emergency Management
USSB4043Intro
25%
A bill to instruct the Secretary of Health and Human Services to issue regulations regarding over-the-counter hearing aids.
[Detail][Text][Discuss]
2022-04-07
To Senate Health, Education, Labor, And Pensions Committee
USHB5657Engross
50%
Establishes a new, separate registration process to facilitate medical marijuana research. Specifically, it directs the Drug Enforcement Administration to register (1) practitioners to conduct medical marijuana research, and (2) manufacturers and dis...
[Detail][Text][Discuss]
2022-04-05
Received in the Senate.
USSB253Engross
50%
A bill to expand research on the cannabidiol and marihuana.
[Detail][Text][Discuss]
2022-03-28
Held at the desk.
USHB7121Intro
25%
To require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in the People's Republic of China, an...
[Detail][Text][Discuss]
2022-03-28
To House Subcommittee on Health
USSB1662PassIncreases the amount of funds each fiscal year that the Food and Drug Administration (FDA) must transfer to the Reagan-Udall Foundation for the FDA and that the National Institutes of Health (NIH) must transfer to the Foundation for the NIH. Specific...
[Detail][Text][Discuss]
2022-03-15
Became Public Law No: 117-101. (TXT | PDF)
USSB3799Intro
25%
Sets out programs and activities primarily to address public health preparedness and response. Specifically, the bill establishes a legislative task force to investigate the COVID-19 pandemic and a White House office to advise on pandemic preparednes...
[Detail][Text][Discuss]
2022-03-15
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
USSB3834Intro
25%
A bill to strengthen medical device supply chains.
[Detail][Text][Discuss]
2022-03-14
To Senate Health, Education, Labor, And Pensions Committee
USHB6009Intro
25%
Automatically terminates the COVID-19 public health emergency declared on January 31, 2020, when the Food and Drug Administration approves a new drug (or authorizes the emergency use of a drug) to treat COVID-19.
[Detail][Text][Discuss]
2022-03-09
Motion to Discharge Committee filed by Mr. Schweikert. Petition No: 117-11. (Discharge petition text with signatures.)
USHB6832Intro
25%
Restricts various presidential and federal authorities related to the acquisition of supplies to combat COVID-19. Specifically, the bill prohibits the President from exercising certain authorities under the Defense Production Act of 1950 to prioritiz...
[Detail][Text][Discuss]
2022-02-25
To House Energy And Commerce Committee
USHB2021Intro
25%
Establishes several environmental justice requirements, advisory bodies, and programs to address the disproportionate adverse human health or environmental effects of federal laws or programs on communities of color, low-income communities, or tribal...
[Detail][Text][Discuss]
2022-02-15
Committee Hearings Held.
USHB6710Intro
25%
To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, ...
[Detail][Text][Discuss]
2022-02-11
To House Energy And Commerce Committee
USSB3588Intro
25%
Expands the scope of research and development activities carried out by the Biomedical Advanced Research and Development Authority (BARDA) to include support for maintaining and improving domestic manufacturing surge capacity and capabilities for vac...
[Detail][Text][Discuss]
2022-02-07
To Senate Health, Education, Labor, And Pensions Committee
USHB6584Intro
25%
To direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes.
[Detail][Text][Discuss]
2022-02-03
To House Energy And Commerce Committee
USSB3516Intro
25%
A bill to require the Secretary of Health and Human Services to provide emergency use authorization with respect to certain COVID-19 diagnostic tests approved for use in the European Union.
[Detail][Text][Discuss]
2022-01-18
To Senate Health, Education, Labor, And Pensions Committee
USSB3498Intro
25%
Establishes programs to support research on endemic fungal diseases and the development of antifungal drugs, with a particular focus on Valley Fever. Endemic fungal diseases are fungal infections that tend to occur in specific geographic areas and af...
[Detail][Text][Discuss]
2022-01-13
To Senate Health, Education, Labor, And Pensions Committee
USSB3493Intro
25%
A bill to require guidance on extending expiration dates for certain drugs, and for other purposes.
[Detail][Text][Discuss]
2022-01-12
To Senate Health, Education, Labor, And Pensions Committee
USHB6377Intro
25%
Requires the Department of Health and Human Services (HHS) to provide free antigen diagnostic tests for COVID-19 (i.e., rapid tests) to U.S. residents. The bill also automatically grants emergency use authorization for rapid tests approved by certain...
[Detail][Text][Discuss]
2022-01-12
To House Subcommittee on Health
USSB3449Intro
25%
A bill to require foreign establishments engaged in the manufacture, preparation, propagation, compounding, or processing of a drug or device to register with the Food and Drug Administration regardless of whether the drug or device undergoes further...
[Detail][Text][Discuss]
2022-01-10
To Senate Health, Education, Labor, And Pensions Committee
USHB6000Intro
25%
Addresses pandemic preparedness and public health issues, caregiver and patient engagement, drug development, insurance coverage, and biomedical research. The Department of Health and Human Services (HHS) must undertake research and other activities ...
[Detail][Text][Discuss]
2022-01-04
To House Biotechnology, Horticulture, and Research Committee
USSB3440Intro
25%
Restricts various presidential and federal authorities related to the acquisition of supplies to combat COVID-19. Specifically, the bill prohibits the President from exercising certain authorities under the Defense Production Act of 1950 to prioritiz...
[Detail][Text][Discuss]
2022-01-04
To Senate Banking, Housing, And Urban Affairs Committee
USHB3537PassEstablishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award ...
[Detail][Text][Discuss]
2021-12-23
Became Public Law No: 117-79. (TXT | PDF)
USSB3427Intro
25%
A bill to authorize the Secretary of Health and Human Services to establish a Neuroscience Center of Excellence.
[Detail][Text][Discuss]
2021-12-16
To Senate Health, Education, Labor, And Pensions Committee
USSB3394Intro
25%
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to emergency use authorization transparency.
[Detail][Text][Discuss]
2021-12-14
To Senate Health, Education, Labor, And Pensions Committee
USHB6207Intro
25%
Generally prohibits animal testing in the evaluation of cosmetic products, and it prohibits the sale or transport of cosmetics developed using animal testing, subject to civil penalties. These prohibitions begin one year after enactment. The bill spe...
[Detail][Text][Discuss]
2021-12-10
To House Subcommittee on Health
USHB3743Engross
50%
Increases the amount of funds each fiscal year that the Food and Drug Administration (FDA) must transfer to the Reagan-Udall Foundation for the FDA and that the National Institutes of Health (NIH) must transfer to the Foundation for the NIH. Specific...
[Detail][Text][Discuss]
2021-12-09
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 181.
USSB3357Intro
25%
Generally prohibits animal testing in the evaluation of cosmetic products, and it prohibits the sale or transport of cosmetics developed using animal testing, subject to civil penalties. These prohibitions begin one year after enactment. The bill spe...
[Detail][Text][Discuss]
2021-12-09
To Senate Health, Education, Labor, And Pensions Committee
USSB1425Intro
25%
Makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Tr...
[Detail][Text][Discuss]
2021-12-08
Placed on Senate Legislative Calendar under General Orders. Calendar No. 179.
USHB6133Intro
25%
To require the Commissioner of Food and Drugs to make available for public inspection all records of information submitted to the Food and Drug Administration in conjunction with authorizing the emergency use of, or licensing, a COVID-19 vaccine.
[Detail][Text][Discuss]
2021-12-03
To House Subcommittee on Health
USHB6106Intro
25%
Terminates on December 1, 2021, certain protections from liability that apply to manufacturers of COVID-19 vaccines. Currently, the liability protections generally expire on October 1, 2024, unless the underlying declaration of emergency is rescinded...
[Detail][Text][Discuss]
2021-12-02
To House Subcommittee on Health
USHB1550Engross
50%
Reauthorizes through FY2026 and expands Department of Health and Human Services activities to educate health care providers and the public about human papillomavirus (HPV), its association with certain cancers, and the importance of HPV vaccines. Spe...
[Detail][Text][Discuss]
2021-12-01
To Senate Health, Education, Labor, And Pensions Committee
USSB3291Intro
25%
Expands various initiatives to address antibiotic resistance. The bill reestablishes the interagency Antimicrobial Resistance Task Force to coordinate and develop efforts addressing antibiotic resistance. The Department of Health and Human Services m...
[Detail][Text][Discuss]
2021-12-01
To Senate Health, Education, Labor, And Pensions Committee
USHB5376Intro
25%
Provides funding, establishes programs, and otherwise modifies provisions relating to a broad array of areas, including education, labor, child care, health care, taxes, immigration, and the environment. (The bill is commonly referred to as the Build...
[Detail][Text][Discuss]
2021-11-19
Motion to reconsider laid on the table.
USHB6017Intro
25%
Restricts government entities from requiring that individuals age 18 or younger receive certain COVID-19 vaccines that were authorized through emergency use and related procedures. Specifically, a federal, state, tribal, territorial, or local governm...
[Detail][Text][Discuss]
2021-11-19
To House Subcommittee on Health
USHB3043Intro
25%
Requires the Department of Health and Human Services, in coordination with the Department of Justice, the Department of Labor, and relevant state agencies, to enter into an arrangement with the National Academy of Sciences in order to study the effec...
[Detail][Text][Discuss]
2021-11-09
To House Subcommittee on Crime, Terrorism, and Homeland Security
USHCR60Intro
25%
This concurrent resolution expresses the sense of Congress for ensuring the speediest end of the COVID-19 pandemic the United States and European governments should unite to enact a World Trade Organization Agreement on Trade-Related Aspects of Intel...
[Detail][Text][Discuss]
2021-11-09
To House Subcommittee on Trade
USSB3184Intro
25%
Restricts government entities from requiring that individuals age 18 or younger receive certain COVID-19 vaccines that were authorized through emergency use and related procedures. Specifically, a federal, state, tribal, territorial, or local governm...
[Detail][Text][Discuss]
2021-11-04
To Senate Health, Education, Labor, And Pensions Committee
USSB2910Intro
25%
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period, and for other purposes.
[Detail][Text][Discuss]
2021-10-20
Star Print ordered on the bill.
USHB4369Engross
50%
Directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants...
[Detail][Text][Discuss]
2021-10-20
To Senate Health, Education, Labor, And Pensions Committee
USHB19Intro
25%
Establishes and modifies several programs and requirements to address prescription drug prices. The bill modifies provisions under Medicare and Medicaid relating to prescription drug coverage and price transparency. Among other changes, the bill requ...
[Detail][Text][Discuss]
2021-10-19
To House Subcommittee on Antitrust, Commercial, and Administrative Law
USHB2148Intro
25%
Establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive...
[Detail][Text][Discuss]
2021-10-19
To House Subcommittee on Antitrust, Commercial, and Administrative Law
USHB2366Intro
25%
Addresses data collection, treatment, harm reduction, and other issues related to substance misuse and addiction. It particularly focuses on opioids, fentanyl, and related substances. Specifically, the bill expands surveillance of fentanyl and relate...
[Detail][Text][Discuss]
2021-10-19
To House Subcommittee on Crime, Terrorism, and Homeland Security
USHB2405Intro
25%
Makes changes to the registration process for conducting research on controlled substances that are included in schedule I of the Controlled Substances Act. Among the changes, the bill does the following: exempts from the registration requirements an...
[Detail][Text][Discuss]
2021-10-19
To House Subcommittee on Crime, Terrorism, and Homeland Security
USHB5566Intro
25%
Establishes programs to support research on endemic fungal diseases and the development of antifungal drugs, with a particular focus on Valley Fever. Endemic fungal diseases are fungal infections that tend to occur in specific geographic areas and af...
[Detail][Text][Discuss]
2021-10-13
To House Subcommittee on Health
USSB2983Intro
25%
Authorizes the Food and Drug Administration (FDA) to create an expedited drug approval process specifically for drugs that are currently approved for sale in certain countries (i.e., a European Economic Area member country, Australia, Canada, Israel,...
[Detail][Text][Discuss]
2021-10-07
To Senate Health, Education, Labor, And Pensions Committee
USHB2883Intro
25%
Makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Tr...
[Detail][Text][Discuss]
2021-09-29
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 31 - 9.
Syndicate content
feedback